Portola Pharmaceuticals, Inc. today announced new interim findings from a Phase 2 proof-of-concept study of its investigational Factor Xa inhibitor antidote, Andexanet alfa, in healthy volunteers who received the Factor Xa inhibitor Eliquis^A .
http://www.benzinga.com/news/13/10/3989716/portola-pharma-issues-results-for-first-phase-2-trial-showing-extended-duration-i
http://www.benzinga.com/news/13/10/3989716/portola-pharma-issues-results-for-first-phase-2-trial-showing-extended-duration-i
No comments:
Post a Comment